Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,678Revenue (TTM) $M1.3Net Margin (%)-19,432.9Altman Z-Score9.8
Enterprise Value $M1,302EPS (TTM) $-5.3Operating Margin %-19,376.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score36.7Pre-tax Margin (%)-19,432.9Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %2.4Quick Ratio6.7Cash flow > EarningsY
Price/Sales1,0255-y EBITDA Growth Rate %36.1Current Ratio6.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-123.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M54.6ROIC % (ttm)-813.7Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 30.7483%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 30.7437%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 30.74-3%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 30.7421%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 30.744%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 30.74-20%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 30.747%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 30.7415%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.51)
$ 30.74372%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.96)
$ 30.74520%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 30.74291%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 30.74217%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-37.28view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-47.65view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-47.65view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-47.65view
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$50-37.18view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$50-37.18view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$50-37.18view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$304.7view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.2892.94view
Barry RichardDirector 2016-03-14Buy75,000$15.66100.57view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US :... Jan 23 2017
Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug Jan 19 2017
Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential Jan 19 2017
FDA 101: What Does 'Orphan Drug Designation' Mean? Jan 17 2017
Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns Jan 17 2017
Bullish and Bearish Reversals in the Market Jan 17 2017
Surge From Bank Earnings Doesn't Last Jan 13 2017
Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : January 12, 2017 Jan 12 2017
Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen Jan 11 2017
Sarepta Therapeutics: Reports of Its Demise Appear 'Greatly Exaggerated' Jan 11 2017
Sarepta Muscular Dystrophy Drug Posts Solid Sales Jan 11 2017
Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs Jan 11 2017
7 Stocks Making Big Moves With Unusual Volume Jan 11 2017
Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock? Jan 11 2017
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US :... Jan 11 2017
Tuesday’s Top Biopharma Movers Jan 10 2017
Sarepta gains $300M in value as Duchenne drug launch beats expectations Jan 10 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)